Drugs / Inosine pranobex

Trials 8 · a red edge is where a trial was stopped

20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00000699 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 41 trial
Phase 4 NCT03883334 Feb 2019 → Mar 2020 HIV infectious disease Universidad San Francisco de Quito Unknown No outcome recorded
Phase not applicable6 trials
NCT00002296 HIV infectious disease, lymphatic system disorder Newport Pharmaceuticals International Completed No outcome recorded
NCT00002295 HIV infectious disease Newport Pharmaceuticals International Completed No outcome recorded
NCT00002059 HIV infectious disease Newport Pharmaceuticals International Completed No outcome recorded
NCT00002060 HIV infectious disease Newport Pharmaceuticals International Completed No outcome recorded
NCT00002061 HIV infectious disease, lymphatic system disorder Newport Pharmaceuticals International Completed No outcome recorded
NCT00002297 HIV infectious disease, lymphatic system disorder Newport Pharmaceuticals International Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT04360122 Comparator May → Nov 2020 COVID-19 Ain Shams University Unknown No outcome recorded
Phase 3 NCT04383717 Comparator May → Aug 2020 respiratory tract infectious disorder Cairo University Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as Inosine pranobex ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002295
6

NCT00002296

NCT00002060

NCT00002061

NCT00000699

NCT00002059

NCT00002297

Known as Isoprinosine “The objective is to determine the effect of Isoprinosine (inosine pranobex) in homosexual male patients with AIDS related complex (ARC) in delaying the onset of AIDS.” NCT00002060
2

NCT04383717

NCT04360122

Known as Metisoprinol ClinicalTrials.gov intervention name — accepted as the source's own label NCT03883334
Route Oral “All patients take INPX capsules 4 times a day and RBV capsules 2 or 3 times a day.” NCT00000699